Secondary Interaction Between MDMX and P53 Core Domain Inhibits P53 DNA Binding

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2016 Apr 27

PMID 27114532

Citations 26

Authors

Xi Wei

Shaofang Wu

Tanjing Song

Lihong Chen

Ming Gao

Wade Borcherds

Gary W Daughdrill

Jiandong Chen

Affiliations

Soon will be listed here.

Abstract

The MDMX oncoprotein is an important regulator of tumor suppressor p53 activity during embryonic development. Despite sequence homology to the ubiquitin E3 ligase MDM2, MDMX depletion activates p53 without significant increase in p53 level, implicating a degradation-independent mechanism. We present evidence that MDMX inhibits the sequence-specific DNA binding activity of p53. This function requires the cooperation between MDMX and CK1α, and phosphorylation of S289 on MDMX. Depletion of MDMX or CK1α increases p53 DNA binding without stabilization of p53. A proteolytic fragment release assay revealed that in the MDMX-p53 complex, the MDMX acidic domain and RING domain interact stably with the p53 DNA binding domain. These interactions are referred to as secondary interactions because they only occur after the canonical-specific binding between the MDMX and p53 N termini, but exhibit significant binding stability in the mature complex. CK1α cooperates with MDMX to inhibit p53 DNA binding by further stabilizing the MDMX acidic domain and p53 core domain interaction. These results suggest that secondary intermolecular interaction is important in p53 regulation by MDMX, which may represent a common phenomenon in complexes containing multidomain proteins.

Citing Articles

Identification and validation of the biomarkers related to ferroptosis in calcium oxalate nephrolithiasis.

Hou C, Zhong B, Gu S, Wang Y, Ji L Aging (Albany NY). 2024; 16(7):5987-6007.

PMID: 38536018 PMC: 11042938. DOI: 10.18632/aging.205684.

MDMX in Cancer: A Partner of p53 and a p53-Independent Effector.

Lin W, Yan Y, Huang Q, Zheng D Biologics. 2024; 18:61-78.

PMID: 38318098 PMC: 10839028. DOI: 10.2147/BTT.S436629.

MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers.

Liu J, Yang J, Pan Q, Wang X, Wang X, Chen H Eur J Med Res. 2024; 29(1):79.

PMID: 38281029 PMC: 10821240. DOI: 10.1186/s40001-024-01684-z.

Protein disorder and autoinhibition: The role of multivalency and effective concentration.

Fenton M, Gregory E, Daughdrill G Curr Opin Struct Biol. 2023; 83:102705.

PMID: 37778184 PMC: 10841074. DOI: 10.1016/j.sbi.2023.102705.

FAM193A is a positive regulator of p53 activity.

Szwarc M, Guarnieri A, Joshi M, Duc H, Laird M, Pandey A Cell Rep. 2023; 42(3):112230.

PMID: 36897777 PMC: 10164416. DOI: 10.1016/j.celrep.2023.112230.

References

Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang Z, Hainaut P . New approaches to understanding p53 gene tumor mutation spectra. Mutat Res. 2000; 431(2):199-209. DOI: 10.1016/s0027-5107(99)00162-1. View

Chen L, Borcherds W, Wu S, Becker A, Schonbrunn E, Daughdrill G . Autoinhibition of MDMX by intramolecular p53 mimicry. Proc Natl Acad Sci U S A. 2015; 112(15):4624-9. PMC: 4403185. DOI: 10.1073/pnas.1420833112. View

Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai K, Yuan Z . DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem. 2003; 278(46):45946-53. DOI: 10.1074/jbc.M308295200. View

Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R . Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol. 2004; 24(13):5835-43. PMC: 480894. DOI: 10.1128/MCB.24.13.5835-5843.2004. View

Gannon J, Greaves R, Iggo R, Lane D . Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990; 9(5):1595-602. PMC: 551855. DOI: 10.1002/j.1460-2075.1990.tb08279.x. View

Shvarts A, Steegenga W, Riteco N, van Laar T, Dekker P, Bazuine M . MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996; 15(19):5349-57. PMC: 452278. View

Haupt Y, Maya R, Kazaz A, Oren M . Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387(6630):296-9. DOI: 10.1038/387296a0. View

Kubbutat M, Jones S, Vousden K . Regulation of p53 stability by Mdm2. Nature. 1997; 387(6630):299-303. DOI: 10.1038/387299a0. View

Bullock A, Henckel J, DeDecker B, Johnson C, Nikolova P, Proctor M . Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A. 1998; 94(26):14338-42. PMC: 24967. DOI: 10.1073/pnas.94.26.14338. View

10.

Stott F, Bates S, James M, McConnell B, Starborg M, Brookes S . The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998; 17(17):5001-14. PMC: 1170828. DOI: 10.1093/emboj/17.17.5001. View

11.

Chen L, Li C, Pan Y, Chen J . Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol Cell Biol. 2005; 25(15):6509-20. PMC: 1190343. DOI: 10.1128/MCB.25.15.6509-6520.2005. View

12.

Chen L, Gilkes D, Pan Y, Lane W, Chen J . ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 2005; 24(19):3411-22. PMC: 1276172. DOI: 10.1038/sj.emboj.7600812. View

13.

Soussi T, Ishioka C, Claustres M, Beroud C . Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer. 2006; 6(1):83-90. DOI: 10.1038/nrc1783. View

14.

Yu G, Rudiger S, Veprintsev D, Freund S, Fernandez-Fernandez M, Fersht A . The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci U S A. 2006; 103(5):1227-32. PMC: 1360574. DOI: 10.1073/pnas.0510343103. View

15.

Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G . Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A. 2006; 103(9):3232-7. PMC: 1413884. DOI: 10.1073/pnas.0508476103. View

16.

Wallace M, Worrall E, Pettersson S, Hupp T, Ball K . Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell. 2006; 23(2):251-63. DOI: 10.1016/j.molcel.2006.05.029. View

17.

Gilkes D, Chen L, Chen J . MDMX regulation of p53 response to ribosomal stress. EMBO J. 2006; 25(23):5614-25. PMC: 1679771. DOI: 10.1038/sj.emboj.7601424. View

18.

Cross B, Chen L, Cheng Q, Li B, Yuan Z, Chen J . Inhibition of p53 DNA binding function by the MDM2 protein acidic domain. J Biol Chem. 2011; 286(18):16018-29. PMC: 3091211. DOI: 10.1074/jbc.M111.228981. View

19.

Pant V, Xiong S, Iwakuma T, Quintas-Cardama A, Lozano G . Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A. 2011; 108(29):11995-2000. PMC: 3141986. DOI: 10.1073/pnas.1102241108. View

20.

Huang L, Yan Z, Liao X, Li Y, Yang J, Wang Z . The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci U S A. 2011; 108(29):12001-6. PMC: 3141917. DOI: 10.1073/pnas.1102309108. View